Boehringer Ingelheim on Open Innovation
The International Business Times reported that open innovation has become a fundamental part of drug discovery, according to the German pharmaceutical company Boehringer Ingelheim. To provide starting points for drug discovery projects, the company has formed bilateral collaboration agreements with academic investigators and biotechnology companies and has engaged in private-public partnerships and crowdsourcing initiatives. As part of these collaborations, Boehringer Ingelheim has partnered with Icahn School of Medicine at Mount Sinai, Massachusetts General Hospital, Scripps Research Institute and Weill Cornell Medicine to find novel therapeutic approaches.
Click here to read the full article.